Prima Biomed // CVac (Eierstock-Krebs) Phase 2a -- MarktKap: 5,8 mio€ - 500 Beiträge pro Seite
eröffnet am 01.01.07 14:37:49 von
neuester Beitrag 01.05.07 09:47:55 von
neuester Beitrag 01.05.07 09:47:55 von
Beiträge: 15
ID: 1.102.857
ID: 1.102.857
Aufrufe heute: 0
Gesamt: 3.068
Gesamt: 3.068
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 20:17 | 702 | |
| 08.05.24, 11:56 | 471 | |
| gestern 17:59 | 309 | |
| heute 01:55 | 260 | |
| gestern 22:26 | 243 | |
| vor 1 Stunde | 219 | |
| heute 00:58 | 189 | |
| gestern 23:30 | 147 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.772,85 | +0,46 | 131 | |||
| 2. | 3. | 0,2170 | +3,33 | 125 | |||
| 3. | Neu! | 8,8800 | +57,45 | 108 | |||
| 4. | 4. | 168,47 | -2,04 | 103 | |||
| 5. | 14. | 5,7540 | -2,18 | 56 | |||
| 6. | 2. | 0,2980 | -3,87 | 50 | |||
| 7. | 5. | 2,5600 | -6,91 | 49 | |||
| 8. | 7. | 6,8000 | +2,38 | 38 |
Feedback
Frohes gesundes und erfolgreiches neues Jahr !
Interessante technologie vergleichbar mit Dendreon´s (DNDN) .
Vorläufige Phase 2a daten sind sehr vielversprechend ,komplette Phase 2a ergebnisse im 1Q 2007.
Biomira hat die Nordamerika rechte mit der option auf Weltweit (ausser Australasia) auszuweiten .
Es besteht auch die möglichkeit das Biomira das Unternehmen ganz übernimmt .
Ich glaube es gibt kaum eine günstigere Biotech aktie mit so hohen chancen .
Prima Biomed (PRR.AX)
Marktkap:9,8 mio A$ // 5,8 mio€
Cash: 3 mioA$
Kurs: 0,05 A$ // 0,03€
Pipeline:
Präsentation Nov.2006:
http://www.primabiomed.com.au/projects/prodDocuments/AGM%20P…
Prima Biomed completes treatment of final patient in Phase IIa trial for ovarian cancer
http://www.primabiomed.com.au/projects/prodDocuments/Treatme…
Positive Results for Prima BioMed’s ongoing Phase IIa Ovarian
Cancer Trial
http://www.primabiomed.com.au/projects/prodDocuments/s%20ong…
Bioshares Report 2006:
http://www.primabiomed.com.au/projects/prodDocuments/Bioshar…
Homepage
http://www.primabiomed.com.au/index2.php
Interessante technologie vergleichbar mit Dendreon´s (DNDN) .
Vorläufige Phase 2a daten sind sehr vielversprechend ,komplette Phase 2a ergebnisse im 1Q 2007.
Biomira hat die Nordamerika rechte mit der option auf Weltweit (ausser Australasia) auszuweiten .
Es besteht auch die möglichkeit das Biomira das Unternehmen ganz übernimmt .
Ich glaube es gibt kaum eine günstigere Biotech aktie mit so hohen chancen .
Prima Biomed (PRR.AX)
Marktkap:9,8 mio A$ // 5,8 mio€
Cash: 3 mioA$
Kurs: 0,05 A$ // 0,03€
Pipeline:
Präsentation Nov.2006:
http://www.primabiomed.com.au/projects/prodDocuments/AGM%20P…
Prima Biomed completes treatment of final patient in Phase IIa trial for ovarian cancer
http://www.primabiomed.com.au/projects/prodDocuments/Treatme…
Positive Results for Prima BioMed’s ongoing Phase IIa Ovarian
Cancer Trial
http://www.primabiomed.com.au/projects/prodDocuments/s%20ong…
Bioshares Report 2006:
http://www.primabiomed.com.au/projects/prodDocuments/Bioshar…
Homepage
http://www.primabiomed.com.au/index2.php
Antwort auf Beitrag Nr.: 26.629.280 von BrauchGeld am 01.01.07 14:37:49hallo brauchgeld
sag mal wo gräbst du denn diese biotechs immer aus??ich verfolge deine postings immer regelmässig,sehr interessant.
asics
sag mal wo gräbst du denn diese biotechs immer aus??ich verfolge deine postings immer regelmässig,sehr interessant.
asics
WKN...
Antwort auf Beitrag Nr.: 26.629.843 von DerBegriffAngst am 01.01.07 17:33:59541644 in D nur in BLN
Umsätze dort anscheinend minimal, meine Statistik verzeichnet innerhalb der letzten zwölf Monate nur einmal einen Umsatz, am 27.10.06 15.000 Stück.
Umsätze dort anscheinend minimal, meine Statistik verzeichnet innerhalb der letzten zwölf Monate nur einmal einen Umsatz, am 27.10.06 15.000 Stück.
Antwort auf Beitrag Nr.: 26.630.147 von antonazubi am 01.01.07 19:14:42@antonazubi
Woher sollen auch die umsätze in D kommen die aktie wird nirgends empfohlen aber genau diese chance sollte man nutzen um von anfang an dabei zu sein.
Wenn die daten positiv sind wird es bestimmt empfehlungen geben aber dann könnte es bereits zu spät sein .
Wenn Primabio etwas bekannter wäre, würde die aktie mindestens um das 4-5fache höher notieren .
Warten wir erstmal die daten ab .
Produkte:
CVac
The CVac product consists of an adjuvant, mannan, attached to a tumour cell surface protein, mucin 1. The product is known as MFP or mannan fusion protein. The treatment is patient-specific and delivered to patients via autologous dendritic cell therapy. The patient’s dendritic cells are isolated from their blood after which MFP is mixed with the cells so as to introduce the protein mucin-1 into and expressed on the surface of the cells. Intellectual property rights to use mucin 1 have been licenced exclusively from Biomira Inc., Canada .
DCtag-CEA
The DCtagTM-CEA product consists of a nanoparticle acting as an adjuvant known as DCtagTM coupled to Carcinoembryonic antigen (CEA). The DCtagTM adjuvant acts as an immune enhancer and CEA is present on a number of cancers such as colon, breast and lung cancers. The combination of DCtagTM and CEA within the same product enables the immune system to recognize and attack tumour cells on which CEA is present.
Partner:
Mersana Inc.
August 2004
Research Agreement
Development of biodegradable nanoparticles for use in vaccines for infectious diseases.
Biomira Inc.
March 2004
Licence & Development Agreement
CancerVac has secured a world wide exclusive licence to mucin-1 for use in dendritic cell therapy for the treatment of cancer. Biomira has an option to secure commercialisation rights for the CVac technology worldwide excluding ANZ.
Prana Biotechnology Ltd.
August 2003
Contract Research
Collaborating on the development of a therapeutic vaccine for Alzheimers Disease using DCtagTM technology.
Medarex Inc.
March 2003
Collaboration Agreement
Collaboration on the development of fully human antibodies to treat cancer (under the Oncomab program).
Insider:
http://au.finance.yahoo.com/q/ait?s=PRR.AX
Date Insider Quantity Traded Security Type Transaction Post Trade Ownership
1/12/06 Eugene Kopp 178,125 Indirect Shares Buy 16,103,461
23/5/06 Eugene Kopp 600,000 Indirect Shares Buy 15,925,336
22/5/06 John Sime 100,000 Indirect Shares Buy 100,000
18/5/06 Eugene Kopp 100,000 Indirect Shares Buy 15,325,336
9/11/05 Eugene Kopp 200,000 Indirect Shares Buy 15,225,336
21/4/05 Eugene Kopp 222,002 Indirect Shares Buy 14,925,336
“Prima has demonstrated early,
interim efficacy for CVacTM which
suggests the vaccine may prove
effective in end-stage patients.
We await the full set of results
in 1Q 2007 but believe that at a
market cap of $10million and the
possibility of a near term license deal,
Prima is one stock to watch in the
therapeutic vaccine space” Dr Thomas
Duthy, Biotechnology Equities
Analyst, Taylor Collison.
Woher sollen auch die umsätze in D kommen die aktie wird nirgends empfohlen aber genau diese chance sollte man nutzen um von anfang an dabei zu sein.
Wenn die daten positiv sind wird es bestimmt empfehlungen geben aber dann könnte es bereits zu spät sein .
Wenn Primabio etwas bekannter wäre, würde die aktie mindestens um das 4-5fache höher notieren .
Warten wir erstmal die daten ab .
Produkte:
CVac
The CVac product consists of an adjuvant, mannan, attached to a tumour cell surface protein, mucin 1. The product is known as MFP or mannan fusion protein. The treatment is patient-specific and delivered to patients via autologous dendritic cell therapy. The patient’s dendritic cells are isolated from their blood after which MFP is mixed with the cells so as to introduce the protein mucin-1 into and expressed on the surface of the cells. Intellectual property rights to use mucin 1 have been licenced exclusively from Biomira Inc., Canada .
DCtag-CEA
The DCtagTM-CEA product consists of a nanoparticle acting as an adjuvant known as DCtagTM coupled to Carcinoembryonic antigen (CEA). The DCtagTM adjuvant acts as an immune enhancer and CEA is present on a number of cancers such as colon, breast and lung cancers. The combination of DCtagTM and CEA within the same product enables the immune system to recognize and attack tumour cells on which CEA is present.
Partner:
Mersana Inc.
August 2004
Research Agreement
Development of biodegradable nanoparticles for use in vaccines for infectious diseases.
Biomira Inc.
March 2004
Licence & Development Agreement
CancerVac has secured a world wide exclusive licence to mucin-1 for use in dendritic cell therapy for the treatment of cancer. Biomira has an option to secure commercialisation rights for the CVac technology worldwide excluding ANZ.
Prana Biotechnology Ltd.
August 2003
Contract Research
Collaborating on the development of a therapeutic vaccine for Alzheimers Disease using DCtagTM technology.
Medarex Inc.
March 2003
Collaboration Agreement
Collaboration on the development of fully human antibodies to treat cancer (under the Oncomab program).
Insider:
http://au.finance.yahoo.com/q/ait?s=PRR.AX
Date Insider Quantity Traded Security Type Transaction Post Trade Ownership
1/12/06 Eugene Kopp 178,125 Indirect Shares Buy 16,103,461
23/5/06 Eugene Kopp 600,000 Indirect Shares Buy 15,925,336
22/5/06 John Sime 100,000 Indirect Shares Buy 100,000
18/5/06 Eugene Kopp 100,000 Indirect Shares Buy 15,325,336
9/11/05 Eugene Kopp 200,000 Indirect Shares Buy 15,225,336
21/4/05 Eugene Kopp 222,002 Indirect Shares Buy 14,925,336
“Prima has demonstrated early,
interim efficacy for CVacTM which
suggests the vaccine may prove
effective in end-stage patients.
We await the full set of results
in 1Q 2007 but believe that at a
market cap of $10million and the
possibility of a near term license deal,
Prima is one stock to watch in the
therapeutic vaccine space” Dr Thomas
Duthy, Biotechnology Equities
Analyst, Taylor Collison.
Trading Spotlight
Antwort auf Beitrag Nr.: 26.630.522 von BrauchGeld am 01.01.07 21:40:22Im Hotcopper board sind so gut wie alle sehr optimistisch und glauben an kurse von mindestens 70cent für 2007.
Artikel von ende Dezemeber 06:
For those who don't have access to Herald Sun article in the BusinessDaily section.
The Melbourne-based biotechnology company last week announced the phase IIa clinical trial of its ovarian cancer immunotherapy treatment Cvac was complete.
Results will be released to the market in the first quarter of 2007. The drug’s first human trial began in 2001 involving 12 patients: the second included 28. If validated, CVac could be administered within five years to ovarian cancer patients, who have received chemotherapy, to boost and activate their weakened immune systems.
“It is a major milestone,” Mr Kopp told BusinessDaily.
“We are looking to complete the final report and initiate a much bigger trial with the support of leading Australian gynaecologists.” Prima Biomed’s portfolio of products is focused in the therapeutic area of cancer and resulted from an affiliation with the Austin Research Institute.
In return for granting Prima Biomed the worldwide right to commercialise identified products more than five years ago, ARI, now merged with the Burnet Institute, became a major shareholder in the junior biotech company.
Mr Kopp said the company was pleased with progress on CVac and the company’s two other projects – a vaccine adjuvant and an antibody therapy.
“We believe there is no question that we have chosen the right path,” he said. “Australian science has had enormous success and CSL’s cervical vaccine is one of those.
“And here, Prima has potentially another significant contribution to make to women’s health and ovarian cancer in particular.”
According to the Victorian Government, biotechnology – and companies such as Prima Biomed – are key to the state’s future prosperity, with potential to generate great economic benefits.
In 2001, the Government announced a strategic development plan for the sector, aiming to position Victoria among the world’s top five biotechnology locations by 2010.
San Francisco and Boston currently rank among the sectors leading worldwide hubs.
Mr Kopp said access to top Australian researchers and lab technicians gave Victoria an edge as a biotechnology base.
“Australia is also low-cost based”, he said.
In line with its commitment to the biotech sector, the State Government earlier this year announced $1 million in funding for an industry partnership to establish a bioprocessing facility in Victoria.
According to Business Victoria, the lack of a pilot-scale mammalian cell manufacturing plant that can produce materials for clinical trials has been a barrier to translating research into reality in Australia.
It hopes companies developing antibody therapies will benefit from access to the facility.
While Prima BioMed has no immediate plans to use the proposed facility, Mr Kopp said the company would consider direct involvement in the future.
“We are currently pursuing animal trials for the generation of antibody therapies in the US,” he said.
“The new bioprocessing facility would allow us to do so at home in Melbourne, potentially at a cost advantage and with more control over product development.”
The Department of Innovation Industry and Regional Development is assessing expression of interest for the development of the fee-for-service facility.
Institute of Drug Technology Australia managing director Graeme Blackman commends the Stage Governments efforts to promote a robust life sciences sector, but believes more needs to be done.
“The commitments tend to favour the basic research end,” he said.
“There is not a big enough commitment at the commercialisation end and that is a weakness in policy.”
Dr Blackman recommended new measures such as payroll tax relief to encourage existing life sciences businesses.
Artikel von ende Dezemeber 06:
For those who don't have access to Herald Sun article in the BusinessDaily section.
The Melbourne-based biotechnology company last week announced the phase IIa clinical trial of its ovarian cancer immunotherapy treatment Cvac was complete.
Results will be released to the market in the first quarter of 2007. The drug’s first human trial began in 2001 involving 12 patients: the second included 28. If validated, CVac could be administered within five years to ovarian cancer patients, who have received chemotherapy, to boost and activate their weakened immune systems.
“It is a major milestone,” Mr Kopp told BusinessDaily.
“We are looking to complete the final report and initiate a much bigger trial with the support of leading Australian gynaecologists.” Prima Biomed’s portfolio of products is focused in the therapeutic area of cancer and resulted from an affiliation with the Austin Research Institute.
In return for granting Prima Biomed the worldwide right to commercialise identified products more than five years ago, ARI, now merged with the Burnet Institute, became a major shareholder in the junior biotech company.
Mr Kopp said the company was pleased with progress on CVac and the company’s two other projects – a vaccine adjuvant and an antibody therapy.
“We believe there is no question that we have chosen the right path,” he said. “Australian science has had enormous success and CSL’s cervical vaccine is one of those.
“And here, Prima has potentially another significant contribution to make to women’s health and ovarian cancer in particular.”
According to the Victorian Government, biotechnology – and companies such as Prima Biomed – are key to the state’s future prosperity, with potential to generate great economic benefits.
In 2001, the Government announced a strategic development plan for the sector, aiming to position Victoria among the world’s top five biotechnology locations by 2010.
San Francisco and Boston currently rank among the sectors leading worldwide hubs.
Mr Kopp said access to top Australian researchers and lab technicians gave Victoria an edge as a biotechnology base.
“Australia is also low-cost based”, he said.
In line with its commitment to the biotech sector, the State Government earlier this year announced $1 million in funding for an industry partnership to establish a bioprocessing facility in Victoria.
According to Business Victoria, the lack of a pilot-scale mammalian cell manufacturing plant that can produce materials for clinical trials has been a barrier to translating research into reality in Australia.
It hopes companies developing antibody therapies will benefit from access to the facility.
While Prima BioMed has no immediate plans to use the proposed facility, Mr Kopp said the company would consider direct involvement in the future.
“We are currently pursuing animal trials for the generation of antibody therapies in the US,” he said.
“The new bioprocessing facility would allow us to do so at home in Melbourne, potentially at a cost advantage and with more control over product development.”
The Department of Innovation Industry and Regional Development is assessing expression of interest for the development of the fee-for-service facility.
Institute of Drug Technology Australia managing director Graeme Blackman commends the Stage Governments efforts to promote a robust life sciences sector, but believes more needs to be done.
“The commitments tend to favour the basic research end,” he said.
“There is not a big enough commitment at the commercialisation end and that is a weakness in policy.”
Dr Blackman recommended new measures such as payroll tax relief to encourage existing life sciences businesses.
Antwort auf Beitrag Nr.: 26.678.176 von BrauchGeld am 04.01.07 18:31:55Prima steigt heute ohne news um über 17% auf 0,06 A$ ,na wenn das mal keine positiven vorzeichen sind .
5d Chart:
5d Chart:
Was für ein super start ,mal sehen wie das endet .
Antwort auf Beitrag Nr.: 26.803.988 von BrauchGeld am 10.01.07 00:35:26Liest sich gut was im update steht aber der kurs wird erst reagieren wenn die ergebnisse da sind .
Ich halte nur eine kleine position von 30tsd stück deshalb kann ich entspannt auf die daten warten ohne schmerzen dabei zuhaben.
Market Update 13.02.2007
http://www.aspecthuntley.com.au/docserver/00692528.pdf?filei…
Growth opportunities for Prima
Proposed pathway for international registration of
CVacTM
– Phase IIb Ovarian Cancer - ANZ
– File Investigational New Drug (IND) application for international
pivotal trial
– A successful pivotal trial may then form the basis of a Biologics
Licence Application for product registration
Considering initiation of a Phase IIa trial for a second
indication
Identification of lead antibody target in the
OncoMab/Medarex JV
Potential for liquidity events for Panvax and Trillium
Therapeutics Inc investments
Ich halte nur eine kleine position von 30tsd stück deshalb kann ich entspannt auf die daten warten ohne schmerzen dabei zuhaben.
Market Update 13.02.2007
http://www.aspecthuntley.com.au/docserver/00692528.pdf?filei…
Growth opportunities for Prima
Proposed pathway for international registration of
CVacTM
– Phase IIb Ovarian Cancer - ANZ
– File Investigational New Drug (IND) application for international
pivotal trial
– A successful pivotal trial may then form the basis of a Biologics
Licence Application for product registration
Considering initiation of a Phase IIa trial for a second
indication
Identification of lead antibody target in the
OncoMab/Medarex JV
Potential for liquidity events for Panvax and Trillium
Therapeutics Inc investments
Antwort auf Beitrag Nr.: 27.690.248 von BrauchGeld am 13.02.07 20:40:27Hoffentlich gute news es können nur die CVac Phase IIa ergebnisse oder eine K.E. sein .
Prima Biomed Placed in Trading Halt, Pending Company Announcement
Monday March 12, 2007, 10:06 am
Original Announcement: Trading Halt
The securities of Prima Biomed will remain in pre-open at the request of the company, until the earlier of the commencement of normal trading on Wednesday, 14 March 2007 or when the company releases an announcement to the market.
Prima Biomed Placed in Trading Halt, Pending Company Announcement
Monday March 12, 2007, 10:06 am
Original Announcement: Trading Halt
The securities of Prima Biomed will remain in pre-open at the request of the company, until the earlier of the commencement of normal trading on Wednesday, 14 March 2007 or when the company releases an announcement to the market.
Antwort auf Beitrag Nr.: 26.629.280 von BrauchGeld am 01.01.07 14:37:49CVac übertrifft erwartungen jetzt brauchen die nur noch eine finanzspritze und wir haben eine aktie mit riesen potential.
http://www.primabiomed.com.au/projects/prodDocuments/PRR%20F…
http://www.primabiomed.com.au/projects/prodDocuments/PRR%20F…
Antwort auf Beitrag Nr.: 28.283.811 von BrauchGeld am 14.03.07 09:20:04Nachbörslich gabs einen kurzen beitrag über Prima Bio im aussie tv.
Cancer drug trial showing promising results
A trial of a new Australian-made treatment for ovarian cancer is producing promising results by reducing cancer markers in some patients by up to 50 per cent.
C-Vac contains some of the patients own white blood cells and works by boosting the patient's immune system, allowing it to recognise and fight the cancer.
Brisbane patient Rosalie Martin is one who has taken part in the trial and has undergone four operations.
"I have sought to find as much information as possible in order to be fully informed about options open to cancer patients," she said.
"It has transformed my life completely and I am very grateful."
http://au.news.yahoo.com/070314/23/12qpy.html
------------
Just watched the News at 6 on 7.
They gave C-Vac a 2 minute spread on the main news bulletin.
Even better they interviewed an Australian woman who was given 3 - 6 months to live about 15 months ago with completely untreatable malignant cancer.
C-Vac cured her completely - lots of film of her looking happy in the sunshine etc...
Plus comments from some PRR directors..
This looks good for tomorrow imo....bound to be in all the newspapers now.
Cancer drug trial showing promising results
A trial of a new Australian-made treatment for ovarian cancer is producing promising results by reducing cancer markers in some patients by up to 50 per cent.
C-Vac contains some of the patients own white blood cells and works by boosting the patient's immune system, allowing it to recognise and fight the cancer.
Brisbane patient Rosalie Martin is one who has taken part in the trial and has undergone four operations.
"I have sought to find as much information as possible in order to be fully informed about options open to cancer patients," she said.
"It has transformed my life completely and I am very grateful."
http://au.news.yahoo.com/070314/23/12qpy.html
------------
Just watched the News at 6 on 7.
They gave C-Vac a 2 minute spread on the main news bulletin.
Even better they interviewed an Australian woman who was given 3 - 6 months to live about 15 months ago with completely untreatable malignant cancer.
C-Vac cured her completely - lots of film of her looking happy in the sunshine etc...
Plus comments from some PRR directors..
This looks good for tomorrow imo....bound to be in all the newspapers now.
Prima ist nach wie vor das günstigste "cancer vaccine company" .
CVac™ CELL THERAPY FACT SHEET
http://www.primabiomed.com.au/projects/prodDocuments/FactShe…
CVac™ CELL THERAPY FACT SHEET
http://www.primabiomed.com.au/projects/prodDocuments/FactShe…
Nach langer zeit mal wieder gute news .......
Prima's final Phase IIa results accepted for poster presentation at US oncology meeting
1 May 2007, Melbourne, Australia: Prima BioMed Limited (ASX:PRR) today announced that final data from its Phase IIa trial of CVacTM in advanced ovarian cancer have been accepted for a poster discussion at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will take place in Chicago, Illinois, June 1-5, 2007.
The poster presentation is titled:
Abstract ID 30962: 'Durable clinical responses in patients with ovarian carcinoma treated on a phase II trial of autologous dendritic cells pulsed with MUC1'.
"We are very pleased that the abstract has been accepted at this prestigious meeting representing our first opportunity to present the results internationally”, stated Mr Eugene Kopp, CEO. "Now that Prima holds worldwide commercialisation rights for CVacTM and is aligning its clinical development program to international requirements, ASCO provides an excellent forum to generate international interest".
The information presented in the poster will also be discussed by a leading authority in Ovarian Cancer. The ASCO Annual Meeting is considered the premier educational and scientific event in the oncology community, attracting more than 29,000 attendees from all over the world in 2006.
Prima's final Phase IIa results accepted for poster presentation at US oncology meeting
1 May 2007, Melbourne, Australia: Prima BioMed Limited (ASX:PRR) today announced that final data from its Phase IIa trial of CVacTM in advanced ovarian cancer have been accepted for a poster discussion at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will take place in Chicago, Illinois, June 1-5, 2007.
The poster presentation is titled:
Abstract ID 30962: 'Durable clinical responses in patients with ovarian carcinoma treated on a phase II trial of autologous dendritic cells pulsed with MUC1'.
"We are very pleased that the abstract has been accepted at this prestigious meeting representing our first opportunity to present the results internationally”, stated Mr Eugene Kopp, CEO. "Now that Prima holds worldwide commercialisation rights for CVacTM and is aligning its clinical development program to international requirements, ASCO provides an excellent forum to generate international interest".
The information presented in the poster will also be discussed by a leading authority in Ovarian Cancer. The ASCO Annual Meeting is considered the premier educational and scientific event in the oncology community, attracting more than 29,000 attendees from all over the world in 2006.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 88 | ||
| 67 | ||
| 50 | ||
| 40 | ||
| 36 | ||
| 20 | ||
| 15 | ||
| 12 | ||
| 12 | ||
| 11 |
